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Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, 
designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data 
as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine 
clinical studies in which the study drug was administered via local wound infiltration.
Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound 
infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients 
received bupivacaine HCl (dose: 75–200 mg) and 190 received placebo. Efficacy measures were 
assessed through 72 hours after surgery.
Results: Overall, 45% of patients were male and 19% were $65 years of age. In the analysis 
of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with 
lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statisti-
cally significant differences compared with bupivacaine HCl (P , 0.05) in five of 17 treatment 
arms. These results were supported by results of other efficacy measures, including time to first 
use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total 
postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction 
with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant 
systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels 
of bupivacaine following administration of liposome bupivacaine were not correlated with local 
efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated.
Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupiva-
caine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical 
pain in soft tissue and orthopedic surgeries.
Keywords: pain, postsurgical; wound infiltration; local anesthetic; analgesic
Introduction
Most patients experience moderate to extreme pain after surgery,1–3 and effective 
postsurgical pain management is a key factor affecting patient recovery.4,5 Multimodal 
analgesia techniques involving analgesics, such as local anesthetics, oral or parenteral 
nonsteroidal anti-inflammatory medications, and oral or parenteral opioids, are recom-
mended as the most safe and effective approach to postsurgical pain control.4
Local anesthetics administered during surgery are frequently used as part of mul-
timodal analgesic regimens; however, the duration of analgesia with these agents is 
short (,12 hours).6–9 Bupivacaine has a long history of use in the surgical setting, and 
the efficacy of bupivacaine HCl administered perioperatively via wound infiltration for 
acute postsurgical pain is well established.6–8,10–12 A novel formulation of   bupivacaine, 
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ie, liposome bupivacaine (Pacira Pharmaceuticals, Inc., 
  Parsippany, NJ), has been developed to address the need for 
longer-acting local anesthetics that can be administered as a 
single dose. This article provides an overview of the efficacy 
profile of liposome bupivacaine based on Phase II and Phase 
III data from 10 randomized, double-blind, controlled, single-
dose wound infiltration studies in patients undergoing hernia 
repair, total knee arthroplasty, hemorrhoidectomy, breast 
augmentation, or bunionectomy.
Materials and methods
All 10 studies were performed in compliance with the Declara-
tion of Helsinki and its amendments and Good Clinical Prac-
tice.13,14 Prior to enrolling patients, each study site obtained 
the approval of its institutional review board and/or ethics 
committee. Written informed consent was obtained from all 
patients or a legal surrogate, or the requirement for written 
informed consent was waived by the ethics committee.
Participants in all studies were adults $18 years of age who 
were scheduled to undergo the specified surgical procedure in 
each study. Patients were excluded if they had a concurrent 
painful physical condition or concurrent surgery that could 
have required analgesic treatment in the postsurgical period 
for pain not strictly related to the surgical wound site being 
administered the study drug; significant medical conditions or 
laboratory results that indicated an increased vulnerability to 
the study drugs and/or procedures; and any clinically signifi-
cant event or condition uncovered during the surgery that might 
have rendered the patient medically unstable or complicated 
the postsurgical course. Patients with a history of opioid or 
alcohol abuse/addiction were also excluded.
Study design
The milligram dose of liposome bupivacaine is expressed as 
the free base (ie, 266 mg of bupivacaine base is chemically 
equivalent to 300 mg of bupivacaine HCl; Table 1). An over-
view of the 10 studies is shown in Table 2.15–21 There were 
three studies that assessed the safety and efficacy of lipo-
some bupivacaine in patients undergoing hemorrhoidectomy 
(studies 4, 7, and 9), two in patients undergoing inguinal 
hernia repair (studies 1 and 2), two in patients undergoing 
total knee arthroplasty (studies 3 and 6), two in patients 
undergoing breast augmentation (studies 5 and 8), and one 
in patients undergoing bunionectomy (study 10). Studies 1 
and 5 included commercially available bupivacaine HCl 
without epinephrine (Marcain® Polyamp Steripack, 0.5%; 
A  straZeneca UK Limited, Bedfordshire, UK) as an active 
comparator; studies 2, 3, 4, 6, 7, and 8 included bupivacaine 
HCl with epinephrine (Marcaine® 0.5% with epinephrine 
1:200,000; Hospira, Inc., Lake Forest, IL); and studies 9 and 
10 included a placebo control arm (0.9% sodium chloride). 
Dose levels of liposome bupivacaine ranged from 66 to 
532 mg across studies. In each study, a single dose of study 
drug was administered intraoperatively via local administra-
tion at the end of surgery (day 1), immediately prior to wound 
closure. When called for by the relevant study protocol, 
patients received other analgesic medications for postsurgical 
pain as part of a multimodal pain management strategy.
Efficacy assessments
Pain intensity after surgery was measured using an 11-point 
numeric rating scale (NRS) where 0 = no pain and 10 = worst 
possible pain. The NRS was used in all studies except study 1, 
in which a 100 mm length visual analog scale (0 = no pain 
and 100 = most severe pain possible) was used to measure 
pain intensity. Pain intensity scores were collected through 
at least 72 hours after study drug administration. Cumulative 
pain score as reflected in the area under the curve (AUC) of 
NRS scores through the last timed assessment, and through 
other time points, were derived for each study. Comparisons of 
mean AUC of NRS scores assessed through 24 and 72 hours 
for each study (except study 5; breast augmentation) while 
patients were at rest are presented in this analysis. Study 
5 was not included in the analysis of AUC of NRS scores 
because patients were given liposome bupivacaine in one 
breast pocket and bupivacaine HCl in the other breast pocket; 
the majority of times that an opioid was taken it could not be 
attributed to pain in either the breast treated with liposome 
bupivacaine or the breast treated with bupivacaine HCl.
Other key efficacy measures included time to first 
postsurgical use of opioid rescue medication, proportion 
Table 1   Milligram  dose  equivalents  for  liposome  bupivacaine 
expressed as the free base and bupivacaine HCl
Dose of liposome bupivacaine  
expressed as the free base (mg)
Equivalent dose of  
bupivacaine HCl (mg)
66 75
93 105
106 120
133 150
155 175
160 180
199 225
266 300
306 345
310 350
399 450
532 600
Abbreviation: HCI, hydrochloride. 
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of patients who received no supplemental opioid rescue 
medication, total amount (mg) of opioid rescue medication 
consumed, and patient and caregiver ratings of satisfac-
tion with postsurgical analgesia. Patient satisfaction was 
measured using a four-point categorical scale (poor to very 
good) in study 1, an 11-point numeric scale (0 = completely 
unsatisfied with analgesia; 10 = completely satisfied with 
analgesia) in   studies 6 and 7, and a five-point categorical 
scale (extremely dissatisfied to extremely satisfied) in studies 
8, 9, and 10. Patient satisfaction ratings were not assessed 
in studies 2, 3, 4, and 5. Blinded care provider satisfaction 
with postsurgical analgesia was measured using a four-
point categorical scale (poor to very good) in study 1 and 
an 11-point numeric scale (0 = completely unsatisfied with 
analgesia; 10 = completely satisfied with analgesia) in stud-
ies 2, 3, 4, 5, and 7. This assessment was not conducted in 
studies 6, 8, 9, and 10.
Data analyses
The calculation of cumulative pain intensity scores (AUC of 
NRS) for each treatment arm in studies 8, 9, and 10 incor-
porated the use of rescue pain medications by imputing 
the worst pain intensity score prior to the use of a pain 
medication and carrying that value forward for a speci-
fied time period based on the half-life of the rescue pain 
medication. This imputation method is referred to as the 
“windowed worst observation carried forward + last obser-
vation carried forward” (wWOCF + LOCF). This method 
was retrospectively applied for analysis of AUC of NRS 
data from the other studies, with the exception of studies 3 
and 6, in which patients used a patient-controlled analge-
sia pump and study 5 in which patients received liposome 
bupivacaine in one breast pocket and bupivacaine HCl in the 
other breast pocket. In studies 3 and 6, the time and amount 
of rescue medication administered was not recorded each 
time the patient-controlled analgesia pump was used. In the 
wWOCF + LOCF analyses, missing scores were replaced in 
one of three ways: by the median score from other patients at 
the same time point in the same treatment group if before the 
first nonmissing score; by LOCF if after the last nonmissing 
score; and by linear interpolation if between two nonmissing 
scores. The intent-to-treat population included all random-
ized patients who received the study drug and was based on 
the treatment group to which patients were randomized. The 
intent-to-treat population was used for analyses of AUC of 
NRS via the wWOCF + LOCF imputation method. Analysis 
of other efficacy measures in each study was conducted using 
the full analysis population, which included all patients who 
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received the study drug, underwent the surgical procedure, 
and had sufficient data to calculate a cumulative pain score 
(AUC of NRS). The safety population included all patients 
who received at least one dose of study drug and was based 
on treatment actually received. For total postoperative 
consumption of opioid rescue medication, all opioids were 
converted to an equianalgesic parenteral morphine amount 
using standard conversion factors.22
Comparisons of liposome bupivacaine with bupivacaine 
HCl or placebo for efficacy measures were made using 
analysis of variance, Cochran–Mantel–Haenszel tests, or log-
rank tests as appropriate. All statistical tests were performed 
against a two-sided alternative hypothesis with a significance 
level of 5% (α = 0.05), and all confidence intervals calculated 
were two-sided 95% confidence intervals.
Results
Liposome bupivacaine was administered to a total of 823 
patients across the 10 studies at doses ranging from 66 mg 
to 532 mg. Results from key efficacy measures in each of the 
10 studies are summarized in Table 2.15–21 Patient disposition 
is summarized in Table 3 and patient demographics and other 
baseline characteristics are shown in Table 4. Since there was 
a #1% difference between the total number of patients for 
each study treatment in the intent-to-treat and safety popu-
lations, the demographics and baseline characteristics were 
expected to be similar in both populations.
Cumulative pain scores
Between-group differences in cumulative pain scores (AUC 
of NRS) through 24 and 72 hours across studies are shown in 
Table 3 Patient disposition (pooled intent-to-treat population)
Liposome bupivacaine Bupivacaine HCl Placebo
#266 mg  
(n = 545)
.266 mg  
(n = 278)
All doses   
(n = 823)
(n = 446) (n = 190)
Patients who terminated early, n (%) 9 (1.7) 35 (12.6) 44 (5.3) 49 (11.0) 6 (3.2)
Reason for early termination, n (%)
  Death 0 0 0 1 (0.2) 0
  Adverse event 0 1 (0.4) 1 (0.1) 2 (0.4) 1 (0.5)
  Lost to follow-up 2 (0.4) 3 (1.1) 5 (0.6) 12 (2.7) 0
  Patient withdrew 3 (0.6) 3 (1.1) 6 (0.7) 6 (1.3) 5 (2.6)
  Other 4 (0.7) 26 (9.4) 30 (3.6) 27 (6.1) 0
  Not reported 0 2 (0.7) 2 (0.2) 1 (0.2) 0
Abbreviation: HCI, hydrochloride.
Table 4 Patient demographics and other baseline characteristics (pooled safety population)
Liposome bupivacaine Bupivacaine HCl* 
(n = 446)
Placebo 
(n = 190) #266 mg  
(n = 545)
.266 mg  
(n = 278)
All doses  
(n = 823)
Age, years, mean (SD)  47.6 (14.2) 55.9 (17.6) 50.4 (15.9) 49.5 (16.7) 45.9 (12.9)
Age category, years, n (%)
 , 40 168 (30.8) 70 (25.2) 238 (28.9) 144 (32.3) 63 (33.2)
  40–64 313 (57.4) 99 (35.6) 412 (50.1) 210 (47.1) 112 (58.9)
 $ 65 64 (11.7) 107 (38.5) 171 (20.8) 92 (20.6) 15. (7.9)
  Not reported 0 2 (0.7) 2 (0.2) 0 0
Sex, n (%)
  Male 304 (55.8) 94 (33.8) 398 (48.4) 179 (40.1) 79 (41.6)
  Female 241 (44.2) 184 (66.2) 425 (51.6) 267 (59.9) 111 (58.4)
Race, n (%)
  Caucasian 469 (86.1) 240 (86.3) 709 (86.1) 384 (86.1) 166 (87.4)
  Non-Caucasian 76 (13.9) 36 (12.9) 112 (13.6) 62 (13.9) 24 (12.6)
  Not reported 0 2 (0.7) 2 (0.2) 0 0
ASA class, n (%)
  1–2 477 (87.5) 182 (65.5) 659 (80.1) 354 (79.4) 187 (98.4)
  3–4 51 (9.4) 84 (30.2) 135 (16.4) 82 (18.4) 3 (1.6)
  Not reported 17 (3.1) 12 (4.3) 29 (3.5) 10 (2.2) 0
Notes: *Bupivacaine HCl doses of 75 mg to 200 mg were used across studies. Bupivacaine HCl with epinephrine 1:200,000 was used in studies 2, 3, 4, 6, 7, 8, 9, and 10. 
Bupivacaine HCl without epinephrine was used in studies 1 and 5.
Abbreviations: ASA, American Society of Anesthesiologists; HCI, hydrochloride; SD, standard deviation.
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Favors control
[bupivacaine HCl (b)
or placebo (p)]
Favors liposome bupivacaine (LB)  24-h cumulative pain score
TKA
Study 3 133 LB vs 150 b
Study 3 266 LB vs 150 b
Study 3 399 LB vs 150 b
Study 3 532 LB vs 150 b
Study 6 532 LB vs 200 b
Breast augmentation
Study 8 600 LB vs 200 b
Hernia repair
Study 1 155 LB vs 100 b
Study 1 199 LB vs 100 b
Study 1 266 LB vs 100 b
Study 1 310 LB vs 100 b
Study 2 93 LB vs 105 b
Study 2 160 LB vs 105 b
Study 2 306 LB vs 105 b
Bunionectomy
Study 10 106 LB vs p
Hemorrhoidectomy
Study 4 66 LB vs 75 b
Study 4 199 LB vs 75 b
Study 4 266 LB vs 75 b
Study 7 266 LB vs 100 b
Study 9 266 LB vs p
Cumulative pain score (AUC0–24 of NRS) difference
−240 −216 −192 −144 −120 −96 −72 −48 −24 02 44 87 2 −168
Figure 1 Cumulative pain score (AUC0–24 of NRS). 
Notes: Differences in AUC for pain at rest from 0 to 24 hours between liposome bupivacaine and control groups. Circles represent the difference in means, and bars 
represent the 95% confidence intervals for the difference in means. The perpendicular zero line indicates no difference between liposome bupivacaine and controls. If a 
confidence interval does not cross the zero line, there is a statistically significant difference (P , 0.05) between liposome bupivacaine and controls.
Abbreviations: AUC, area under the curve; HCI, hydrochloride; NRS, numeric rating scale; TKA, total knee arthroplasty.
Figures 1 and 2, respectively. In general, the higher doses of 
liposome bupivacaine were associated with lower cumulative 
pain scores compared with placebo and bupivacaine HCl. 
In the cumulative pain (AUC of NRS) analysis, there were 
17 treatment arms comparing liposome bupivacaine with 
bupivacaine HCl in active control studies. Between-group 
differences were statistically significant in favor of liposome 
bupivacaine in six of these treatment arms through 24 hours 
and in five treatment arms through 72 hours (P , 0.05).
Time to first postsurgical use of opioid 
rescue medication
The time to first postsurgical use of supplemental opioid pain 
medication was pooled across studies (except study 5) for 
all liposome bupivacaine doses combined, for bupivacaine 
HCl, and for placebo (Table 5). The median time to first 
postsurgical use of rescue opioid medication was significantly 
longer with liposome bupivacaine (9.3 hours) compared 
with bupivacaine HCl (6.4 hours; P = 0.013) and placebo 
(3.6 hours; P , 0.0001).
Proportion of patients avoiding  
use of opioid rescue medication
In study 9 (hemorrhoidectomy), the proportion of patients 
avoiding rescue medication through 72 hours after surgery 
was significantly lower in favor of liposome bupivacaine 
266 mg (28% avoided use of rescue opioids) compared with 
placebo (10% avoided use of rescue opioids; P = 0.0007). 
Between-group differences did not reach statistical sig-
nificance in the other placebo-controlled Phase III study 
(study 10), or the seven studies that included comparisons 
of liposome bupivacaine with bupivacaine HCl. Study 5 
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did not include a statistical comparison between liposome 
bupivacaine and bupivacaine HCl for this efficacy measure 
because patients received liposome bupivacaine in one breast 
and bupivacaine HCl in the other breast.
Total postsurgical consumption  
of opioid rescue medication
Total postsurgical consumption of opioid rescue medi-
cation was statistically significantly lower for liposome 
bupivacaine–treated patients than for the comparator in 
four studies (two active-controlled, two placebo-controlled) 
at 24 hours postsurgery, and in two studies (one active-
  controlled, one placebo-controlled) at 72 hours postsurgery 
(Table 6). The higher doses of liposome bupivacaine (266 mg 
and 532 mg) were more frequently associated with a signifi-
cant reduction in total postsurgical consumption of opioids 
than lower doses. There were no statistically significant differ-
ences observed between the liposome bupivacaine treatment 
arms and bupivacaine HCl in the other studies.
Patient and blinded care provider 
satisfaction with postoperative analgesia
In the studies that included assessment of patient rat-
ings of postsurgical analgesia (studies 1, 6, 7, 8, 9, and 
10), the liposome bupivacaine group in study 9 showed 
statistically significantly   better patient satisfaction 
scores than the comparator. At 24 hours after surgery 
in this study, 95% of patients in the liposome bupiva-
caine 266 mg group were “satisfied” or “extremely satisfied” 
with their postoperative analgesia compared with 72% in 
the placebo group (P = 0.0007). At 72 hours after surgery, 
percentages were 95% and 73%, respectively (P = 0.0007). 
Favors control
[bupivacaine HCl (b) or placebo (p)]
Favors liposome bupivacaine (LB)  72-h cumulative pain score
TKA
Study 3 133 LB vs 150 b
Study 3 266 LB vs 150 b
Study 3 399 LB vs 150 b
Study 3 532 LB vs 150 b
Study 6 532 LB vs 200 b
Breast augmentation
Study 8 600 LB vs 200 b
Hernia repair
Study 1 155 LB vs 100 b
Study 1 199 LB vs 100 b
Study 1 266 LB vs 100 b
Study 1 310 LB vs 100 b
Study 2 93 LB vs 105 b
Study 2 160 LB vs 105 b
Study 2 306 LB vs 105 b
Hemorrhoidectomy
Study 4 66 LB vs 75 b
Study 4 199 LB vs 75 b
Study 4 266 LB vs 75 b
Study 7 266 LB vs 100 b
Study 9 266 LB vs p
Bunionectomy
Study 10 106 LB vs p
−240 −216 −192 −144 −120 −96 −72 −48 −24 02 44 87 2 −168
 Cumulative pain score (AUC0–72 of NRS) difference
Figure 2 Cumulative pain score (AUC0–72 of NRS).
Notes: Differences in AUC for pain at rest from 0 to 72 hours between liposome bupivacaine and control groups. Circles represent the difference in means and bars 
represent the 95% confidence intervals for the difference in means. The perpendicular zero line indicates no difference between liposome bupivacaine and controls. If a 
confidence interval does not cross the zero line, there is a statistically significant difference (P , 0.05) between liposome bupivacaine and controls.
Abbreviations: AUC, area under the curve; HCI, hydrochloride; NRS, numeric rating scale; TKA, total knee arthroplasty.
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The other studies showed no statistically significant between-
group differences for this assessment.
For assessments of care provider satisfaction with post-
operative analgesia (studies 1, 2, 3, 4, 5, and 7), statistically 
significant differences were observed between the liposome 
bupivacaine and bupivacaine HCl groups in study 1 at 
24 hours, where 100% of care providers of patients in the 
liposome bupivacaine 199 mg group rated satisfaction as 
“good” or “very good” on a categorical scale versus 81% in 
the bupivacaine HCl 100 mg group (95% confidence interval 
for difference in percentages, 4.1–34.4). Statistically signifi-
cant differences in favor of liposome bupivacaine were also 
observed in study 3, where mean satisfaction ratings, based on 
an 11-point NRS (0 = completely unsatisfied; 10 =   completely 
satisfied), were 9.2 in the liposome bupivacaine 532 mg group 
and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) 
at day 8, and in study 4 where mean ratings in the liposome 
bupivacaine 266 mg and bupivacaine HCl 75 mg groups 
were 7.4 and 6.0, respectively (P = 0.03) at 96 hours. 
No statistically significant between-group differences were 
observed for this assessment in the other studies.
Liposome bupivacaine was well tolerated across the 
823 patient exposures in these 10 studies, and the adverse 
event profile was similar for liposome bupivacaine and 
  bupivacaine HCl. Overall, 62% (508 of 823) of patients 
treated with liposome bupivacaine reported at least one 
adverse event compared with 75% (334 of 446) for 
  bupivacaine HCl and 43% (82 of 190) for placebo. The 
incidence of adverse events generally increased with increas-
ing doses of either liposome bupivacaine or bupivacaine 
HCl. Nausea, constipation, and vomiting were the most 
frequently reported adverse events in patients who received 
liposome bupivacaine or bupivacaine HCl; these adverse 
events are frequently reported in patients receiving opioid 
medications.
Discussion
The highly subjective nature of pain perception and mea-
surement is an inherent limitation of all pain studies. To 
mitigate this limitation, clinical studies conducted in the pain 
setting are typically designed to involve multiple metrics 
for measurement of treatment-related efficacy. Most wound 
Table 5 Time to first postsurgical use of supplemental opioid pain 
medication through 72 hours (pooled intent-to-treat population)
Liposome 
bupivacaine  
(n = 780)
Bupivacaine  
HCl  
(n = 409)
Placebo  
(n = 190)
Number of patients  
who used supplemental  
medication
619 343 180
Quartiles* (hours)
  First quartile 1.8 0.7 1.2
  Median (95% CI) 9.3 (7.6, 11.0)† 6.4 (4.2, 8.5) 3.6 (2.8, 4.0)
  Third quartile 31.8 25.3 5.4
Notes: *First quartile, 25% started using pain medication; median, 50% started using 
pain medication; third quartile, 75% started using pain medication; †P = 0.013 versus 
bupivacaine HCl and P , 0.0001 versus placebo. 
Abbreviations: CI, confidence interval; HCI, hydrochloride. 
Table 6 Total postsurgical consumption of opioid rescue medication: studies with statistical differences between treatment groups
Study 419
Adjusted geometric mean total consumption through 24 hours (mg) Adjusted geometric mean total consumption through 72 hours (mg)
LB 66  
(n = 25)
LB 199  
(n = 25)
LB 266  
(n = 25)
B 75  
(n = 25)
LB 66  
(n = 25)
LB 199  
(n = 25)
LB 266  
(n = 25)
B 75  
(n = 25)
8.0 7.2 4.2* 8.9 15.0 10.0 6.2† 18.4
Study 820
Mean total consumption through 24 hours (mg) Mean total consumption through 72 hours (mg)
LB 532  
(n = 60)
B 200  
(n = 62)
LB 532  
(n = 60)
B 200  
(n = 62)
6.1* 9.3 13.5 20.4
Study 917
Adjusted geometric mean total consumption through 24 hours (mg) Adjusted geometric mean total consumption through 72 hours (mg)
LB 266  
(n = 94)
Placebo  
(n = 93)
LB 266  
(n = 94)
Placebo  
(n = 93)
5.4‡ 12.9 9.9† 18.2
Study 1016
Adjusted geometric mean total consumption through 24 hours (mg) Adjusted geometric mean total consumption through 72 hours (mg)
LB 106  
(n = 97)
Placebo  
(n = 96)
LB 106 
(n = 97)
Placebo  
(n = 96)
3.8† 4.7 11.3 11.1
Notes: *P , 0.05; †P , 0.01; ‡P , 0.0001.
Abbreviations: B, bupivacaine HCl (hydrochloride); LB, liposome bupivacaine. 
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infiltration studies in the liposome bupivacaine develop-
ment program included an assessment of cumulative pain 
over time as the primary efficacy measure, while secondary 
measures focused on outcomes such as pain intensity scores 
and opioid usage at specific time points. Pooling of the effi-
cacy data allowed for a more detailed analysis of outcome 
measures that were utilized across studies. In this pooled 
analysis of efficacy, results from 823 patients who received 
single-dose, locally administered liposome bupivacaine 
across 10 studies in five different surgical models, liposome 
bupivacaine was shown to provide prolonged analgesia for 
up to 72 hours after surgery. Across seven active-controlled 
studies, there were 17 treatment arms comparing liposome 
bupivacaine and bupivacaine HCl. Between-group differ-
ences in cumulative pain scores trended in favor of liposome 
bupivacaine through 72 hours postsurgery in 14 of the 17 
treatment arms, reaching statistical significance (P , 0.05) 
in five treatment arms. Cumulative pain scores trended in 
favor of bupivacaine HCl in three of the 17 treatment arms, 
none of which reached statistical significance at any timed 
assessment.
The cumulative pain score results were supported by the 
results of other efficacy measures. The median time to first 
postsurgical use of supplemental opioid pain medication was 
3 hours later with liposome bupivacaine versus bupivacaine 
HCl (P = 0.013) and 6 hours later than placebo (P , 0.0001). 
Between-group differences in proportion of patients who 
avoided use of rescue opioids and total consumption of res-
cue opioids after surgery also trended in favor of liposome 
bupivacaine in most of the studies analyzed. The greatest 
reductions in opioid use were observed in the treatment 
arms that received the highest doses of liposome bupivacaine 
(266 mg or 532 mg). Also, the between-group comparisons 
showed the higher dose levels of liposome bupivacaine 
were more frequently associated with higher patient and 
caregiver satisfaction scores than lower dose levels. Local 
infiltration of liposome bupivacaine resulted in significant 
systemic plasma levels of bupivacaine, which could persist 
for 96 hours; systemic plasma levels of bupivacaine following 
administration of liposome bupivacaine were not correlated 
with local efficacy.
A limitation of this post hoc analysis is that the results 
cannot be extrapolated to surgical models not examined in 
the 10 studies pooled for this analysis or to patient popula-
tions receiving liposome bupivacaine via administration 
routes other than wound infiltration. Pooling of efficacy 
results was not prespecified in protocols for the individual 
studies.
Conclusion
In conclusion, treatment with liposome bupivacaine resulted 
in lower pain scores and reduced opioid consumption during 
the first 72 hours after surgery in several surgical models. 
A reduction in postsurgical pain may result in less need for 
supplemental opioid pain medications, fewer opioid-related 
adverse events, and a better recovery experience for patients, 
which may offer an economic benefit to health care systems. 
Based on this retrospective integrated analysis of multiple 
efficacy measures, liposome bupivacaine appears to be a 
potentially useful therapeutic option for prolonged reduction 
of postsurgical pain in soft tissue and orthopedic surgeries.
Acknowledgment
The authors acknowledge Barbara Elashoff for her 
assistance with the statistical analysis. 
Disclosure
Editorial assistance was provided by Peloton Advantage, 
LLC, and supported by Pacira Pharmaceuticals, Inc. SDB 
has received research support from Pacira Pharmaceuticals, 
Inc. GP is an employee of Pacira Pharmaceuticals, Inc. SR, 
KB, SRG, and KAC report no conflicts of interest in this 
work.
References
  1.  Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experi-
ence: results from a national survey suggest postoperative pain continues 
to be undermanaged. Anesth Analg. 2003;97(2):534–540.
  2.  Warfield CA, Kahn CH. Acute pain management. Programs in 
US   hospitals and experiences and attitudes among US adults. 
A  nesthesiology. 1995;83(5):1090–1094.
  3.  Beauregard L, Pomp A, Choiniere M. Severity and impact of pain after 
day-surgery. Can J Anaesth. 1998;45(4):304–311.
  4.  Practice guidelines for acute pain management in the perioperative 
  setting: an updated report by the American Society of Anesthesiologists 
Task Force on Acute Pain Management. Anesthesiology. 2012;116(2): 
248–273.
  5.  White PF. Multimodal analgesia: its role in preventing postoperative 
pain. Curr Opin Investig Drugs. 2008;9(1):76–82.
  6.  Jirasiritham S, Tantivitayatan K, Jirasiritham S. Perianal blockage with 
0.5% bupivacaine for postoperative pain relief in hemorrhoidectomy.   
J Med Assoc Thai. 2004;87(6):660–664.
  7.  Chester JF, Stanford BJ, Gazet JC. Analgesic benefit of locally injected 
bupivacaine after hemorrhoidectomy. Dis Colon Rectum. 1990; 
33(6):487–489.
  8.  Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic 
review of preemptive analgesia for postoperative pain relief: the role of 
timing of analgesia. Anesthesiology. 2002;96(3):725–741.
  9.  Moiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A qualitative   
systematic review of incisional local anaesthesia for postoperative   
pain relief after abdominal operations. Br J Anaesth. 1998;81(3): 
377–383.
  10.  Yoost TR, McIntyre M, Savage SJ. Continuous infusion of local 
anesthetic decreases narcotic use and length of hospitalization after 
laparoscopic renal surgery. J Endourol. 2009;23(4):623–626.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
115
Liposome bupivacaine for postsurgical analgesiaJournal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2012:5
  11.  Mahabir RC, Peterson BD, Williamson JS, Valnicek SM, Williamson DG,   
East WE. Locally administered ketorolac and bupivacaine for control 
of postoperative pain in breast augmentation patients. Plast Reconstr 
Surg. 2004;114(7):1910–1916.
  12.  Wheatley GH III, Rosenbaum DH, Paul MC, et al. Improved pain 
management outcomes with continuous infusion of a local anes-
thetic after thoracotomy. J Thorac Cardiovasc Surg. 2005;130(2): 
464–468.
  13.  International Conference on Harmonisation Working Group. ICH 
Harmonised Tripartite Guideline: Guideline for Good Clinical Prac-
tice E6 (R1). International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use; June 
10, 1996; Washington, DC. Available at: http://www.ich.org/fileadmin/
Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/
E6_R1__Guideline.pdf. Accessed March 1, 2011.
  14.  World Medical Association. Declaration of Helsinki: ethical principles 
for medical research involving human subjects. Available at: http://www.
wma.net/en/30publications/10policies/b3/17c.pdf. Accessed April 26, 
2010.
  15.  Bramlett KW, Jones RK, Pink M, Pink T. A single administration of 
DepoBupivacaine intraoperatively provides analgesia and reduction in 
use of rescue opiates compared to bupivacaine HCl in patients undergo-
ing total knee arthroplasty [Abstract 0278]. Presented at the XXXVI 
Biennial World Congress of the International College of Surgeons, 
December 3–6, 2008, Vienna, Austria.
  16.  Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled 
trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local 
analgesic) in bunionectomy. Adv Ther. 2011;28(9):776–788.
  17.  Gorfine S, Krivokapic Z. Extended-release multivesicular liposome 
bupivacaine (Exparel™) is superior to placebo for posthemorrhoid-
ectomy pain reduction [Abstract P230]. Dis Colon Rectum. 2011; 
54(5):174.
  18.  Langford RM, Chappell GM, Karrasch JA. A single administration 
of DepoBupivacaine intraoperatively results in prolonged detectable 
plasma bupivacaine and analgesia in patients undergoing inguinal 
hernia repair [Abstract P-9088]. Presented at the Annual   Postgraduate 
Assembly in Anesthesiology of the New York State Society of 
  Anesthesiologists, December 12–16, 2008, New York, NY.
  19.  Miller H, Terem TM, Kheladze K, Mosidze B. A single administration 
of DepoBupivacaine intraoperatively provides three-day analgesia 
and reduction in use of rescue opioids in patients undergoing hem-
orrhoidectomy [Abstract]. Presented at the Annual Meeting of the 
American Society of Colon and Rectal Surgeons, May 2–6, 2009, 
Hollywood, FL.
  20.  Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy 
and safety of DepoFoam® bupivacaine in patients undergoing bilateral, 
cosmetic, submuscular augmentation mammoplasty: a randomized, 
double-blind, active-control study. Aesthet Surg J. 2012;32(1):69–76.
  21.  White PF, Schooley GL, Ardeleanu M. Analgesia following a single 
administration of depobupivacaine intraoperatively in patients under-
going inguinal herniorrhaphy: preliminary dose-ranging studies   
[Abstract S-242]. Anesth Analg. 2009;108 Suppl 3S:S242.
  22.  Reisine T, Pasternak G. Opioid analgesics and antagonists. In: 
Hardman JG, Limbard LE, Molinoff PB, editors. Goodman and 
Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York, 
NY: McGraw-Hill; 1996.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
116
Bergese et al